Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hers vs PauseRX

Hers
Graded #353

Lower grade

vs+7.8
PauseRX
Graded #163

Higher grade

The verdict

PauseRX takes it — 68.5/100 to 60.7/100.

PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and publishes a full FDA compounded-medication disclaimer.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePauseRX +12
54
66
Dose & formulationPauseRX +8
77
85
Clinical oversightPauseRX +28
55
83
Labs & monitoringEven
52
52
FulfillmentHers +20
81
61
Contract termsEven
41
41
Hers · left barPauseRX · right bar

The numbers

MetricHersPauseRX
WeighScore60.7/10068.5/100
GradeCC
Scorecard rank#353#163
Semaglutide$199/mo (starting dose, compounded)$199/mo
Tirzepatide$299/mo (starting dose, plus a separate fee, brand-name)$249/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Hers

Graded #353 · C

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.

Strengths

  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
  • FDA issued Hims & Hers Health, Inc. dba Hers a warning letter in September 2025; the letter is public in FDA's warning-letter database
PauseRX

Graded #163 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Another provider to compare: CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard